NCT07179055

An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

An Eight-Week, Double-Masked, Randomized, Placebo-Controlled, Phase 2, Evaluation of the Safety and Efficacy of VSJ-110 Ophthalmic Solution in the Treatment of Dry Eye

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 160 (estimated)
• Sponsor: Vanda Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.

Conditions

• Dry Eye

Interventions

Type	Name	Description
DRUG	VSJ-110	ophthalmic solution
DRUG	Placebo	ophthalmic solution

Timeline

• Start date: 2025-10-01
• Primary completion: 2026-09-01
• Completion: 2026-09-01
• First posted: 2025-09-17
• Last updated: 2025-09-17

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study